the aid library

LIST OPTIONS

Filter

5684

National hiv testing services communication strategy 2015 - 2019

National AIDS STI Control Programme (NASCOP), Ministry of Health, Government of Kenya (2015) C1

Strategic communication is used to raise awareness of issues among specific target populations. It aims to provide timely, evidence-based, authoritative information and guidance needed for public health action. Proper implementation of strategic communication leads t... more

Download (724)

View PDF (766)

A case study of the Essential Health Benefit in Tanzania mainland

Todd G.; Nswilla A.; Kisanga O.; Mamdani M. Regional Network for Equity in Health in east and southern Africa (EQUINET) (2017) C1

Regional Network for Equity in Health in east and southern Africa (EQUINET): Disussion Paper 109
This report describes the evolution of mainland Tanzania’s EHB; the motivations for developing the EHBs, the methods used to develop, define and cost them; how it is being disseminated, communicat... more

Download (397)

View PDF (550)

WHO operational handbook on tuberculosis: module 2: screening: systematic screening for tuberculosis disease

World Health Organization WHO (2020) C_WHO

External Link

The path that ends AIDS: UNAIDS Global AIDS Update 2023
recommended

UN Children's Fund UNICEF (2023) CC

This report makes clear that there is a path to end AIDS. Taking that path will help ensure preparedness to address other pandemic challenges, and advance progress across the Sustainable Development Goals. The data and real-world examples in the report make it very clear what that path is. It is not... more

External Link

Acute Chagas Disease: New Global Challenges for an Old Neglected Disease

Andrade, D.; Gollob, K.; Dutra, W. PLoS Neglected Tropical diseases (2015) CC

Abstract: Chagas disease is caused by infection with the protozoan Trypanosoma cruzi, and although over 100 years have passed since the discovery of Chagas disease, it still presents an increasing problem for global public health. A plethora of information concerning the chronic phase of human Chaga... more

Download (280)

View PDF (276)

In all our Diversity 2015 Highlights

J. Bushee; R. Gustav; J.Hows; et al. GNP+ (Global Network of people living with HIV) (2016) C2

Download (368)

View PDF (371)

Teachers for All: Inclusive Teaching for Children with Disabilities Collaborating globally to promote Inclusive Development

Ingrid Lewis and Sunit Bagree International Disability and Development Consortium’s Inclusive Education Task Group (2013) CC

Download (501)

View PDF (531)

Introducing and scaling up testing for human papillomavirus as part of a comprehensive programme for prevention and control of cervical cancer

World Health Organization WHO (2020) C_WHO

This guidance is intended to be used by programme managers following the decision to introduce human papillomavirus (HPV) virological testing as a screening assay in their national cervical cancer prevention and control programme. The guidance includes a step-by-step process to be followed after the... more

Download (345)

View PDF (498)

Trastorno por déficit de atención con hiperactividad

T. S. Moriyama; A. J. M. Cho; R. E. Verin; et al. IACAPAP (2017) C2

Trastornos externalizantes Capítulo D.1 Edición: Matías Irarrázaval & Andrés Martín Traducción: Fernanda Prieto Tagle, Marta García Acuña

Download (359)

View PDF (364)

Multi-Professional Patient Safety Curriculum Guide

World Health Organization WHO (2011) C_WHO

The Multi-professional Patient Safety Curriculum Guide (2011) was developed to assist in the teaching of patient safety in universities and schools in the fields of dentistry, medicine, midwifery, nursing and pharmacy. It also supports the on-going training of all health care professionals. The C... more

Download (249)

View PDF (239)

The Global State of Harm Reduction 2016

K. Stone; G. Sander Harm Reduction International (2016) C2

Download (189)

View PDF (202)

Breast and cervical cancer screening services in Malawi: a systematic review

Pittalis, C.; Panteli, E.; Schouten, E. et al. BMC (2020) CC2

To identify and to assess factors enhancing or hindering the delivery of breast and cervical cancer screening services in Malawi with regard to accessibility, uptake, acceptability and effectiveness. Systematic review of published scientific evidence. A search of six bibliographic databases and gre... more

Download (262)

View PDF (535)

Recomendaciones para el tratamiento hospitalario de la COVID-19 en pacientes adultos ( Version 10, 2020)

G, Zambrano, E Salgato, F. M. Moyano et al. (2020) CC

Recommendations for in-patient management of COVID-19 in adult patients Version 10, November 2020.

Download (242)

View PDF (418)

Pediatric oncology nursing practice in Latin America and the Caribbean

Pan American Health Organisation PAHO (2024) C_WHO

One of the main aims of the WHO Global Initiative for Childhood Cancer and the CureAll Americas framework is to strengthen centers of excellence and promote the training of the health workforce, especially pediatric oncology nurses, specialized in nursing care for children and adolescents with cance... more

Download (851)

View PDF (1870)

Guidance on oral pre-exposure prophylaxis (PrEP) for serodiscordant couples, men and transgender women who have sex with men at high risk of HIV: recommendations for use in the context of demonstratio

World Health Organization (2012)

Download (1485)

View PDF (1782)

Basic Epidemiology

Bonita, R.; R.Beaglehole, and T. Kjellström World Health Organization WHO (2006) C_WHO

2nd edition

Download (409)

View PDF (515)

Planning, Monitoring and Evaluation. Webinar 14. Companion Technical Booklet

Mont, D. UNICEF (2014)

Download (459)

View PDF (692)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (2470)

View PDF (2776)

WHO-WPR Emergency Response Manual

World Health Organization, Western Pacific Office (2003)

Guidelines for WHO Representatives and Country Offices in the Western Pacific Region

Download (489)

View PDF (1190)

An Invisible Crisis: Exploring Mental Health needs in the Syrian and Iraqi Crises

Médecins du Monde (2018) C1

It highlights the numerous challenges to quality service provision, along with the organisation’s response to mental health needs, and recommendations for international and regional decision-makers including: - Advocating and working towards mental health policies that support adequate funding f... more

The path that ends AIDS: UNAIDS Global AIDS Update 2023 recommended

The path that ends AIDS: UNAIDS Global AIDS Update 2023
recommended